United Services Automobile Association increased its position in Bruker Co. (NASDAQ:BRKR) by 11.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,256 shares of the medical research company’s stock after acquiring an additional 3,343 shares during the period. United Services Automobile Association’s holdings in Bruker were worth $1,661,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its stake in Bruker by 0.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 29,691,185 shares of the medical research company’s stock worth $1,483,075,000 after acquiring an additional 180,171 shares during the last quarter. Vanguard Group Inc. raised its stake in Bruker by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 10,866,673 shares of the medical research company’s stock worth $542,789,000 after acquiring an additional 156,591 shares during the last quarter. Janus Henderson Group PLC raised its stake in Bruker by 1.1% in the 2nd quarter. Janus Henderson Group PLC now owns 3,335,079 shares of the medical research company’s stock worth $166,587,000 after acquiring an additional 36,643 shares during the last quarter. D. E. Shaw & Co. Inc. raised its stake in Bruker by 1.2% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 1,924,095 shares of the medical research company’s stock worth $96,109,000 after acquiring an additional 22,812 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Bruker by 2,436.8% in the 2nd quarter. Invesco Ltd. now owns 1,698,456 shares of the medical research company’s stock worth $84,838,000 after acquiring an additional 1,631,502 shares during the last quarter. Institutional investors own 66.59% of the company’s stock.
In other news, CEO Burkhard Prause sold 15,702 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $42.96, for a total transaction of $674,557.92. Following the sale, the chief executive officer now directly owns 1,338 shares in the company, valued at approximately $57,480.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Mark Munch sold 47,203 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $42.87, for a total value of $2,023,592.61. Following the sale, the vice president now owns 96,063 shares in the company, valued at $4,118,220.81. The disclosure for this sale can be found here. 26.50% of the stock is owned by company insiders.
Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, August 1st. The medical research company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.02. Bruker had a return on equity of 27.10% and a net margin of 9.57%. The company had revenue of $490.20 million for the quarter, compared to the consensus estimate of $477.70 million. During the same period last year, the firm earned $0.25 EPS. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. Analysts forecast that Bruker Co. will post 1.61 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Tuesday, September 3rd were given a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.37%. The ex-dividend date of this dividend was Friday, August 30th. Bruker’s dividend payout ratio (DPR) is presently 11.43%.
BRKR has been the topic of several analyst reports. Bank of America raised Bruker from a “neutral” rating to a “buy” rating and set a $52.00 price target on the stock in a research report on Thursday, September 26th. ValuEngine downgraded Bruker from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Jefferies Financial Group increased their price target on Bruker from $45.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. BidaskClub downgraded Bruker from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Finally, Barclays reaffirmed a “hold” rating and set a $44.00 price target on shares of Bruker in a research report on Monday, June 24th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $49.90.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: Market Perform
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.